Neuro-Oncology: MicroRNAs as Biomarkers in Pituitary Tumors

Saturday, July 26, 2014

MicroRNAs as Biomarkers in Pituitary Tumors

Neurosurgery - Current Issue

The use of extracellular microRNAs (miRNAs) as circulating biomarkers is currently leading to relevant advances in the diagnosis and assessment of prognosis of several diseases. Specific miRNAs have also been shown to play a role in the pathophysiology of many neoplastic and non-neoplastic diseases. A number of studies have demonstrated that miRNAs show differential expression in various tumors, such as in the prostate, ovary, lung, breast, brain, and pituitary. Recent findings have built connections between miRNAs that are deregulated within the tumor and their presence in peripheral blood. MiRNAs have been shown to be stable in the blood where they are present in either free and/or uncomplexed form, as well as packed in microvesicles, exosomes, and apoptotic bodies, or bound to different proteins. Because the pituitary is a highly vascularized organ that releases hormones into the circulation, miRNAs would be useful biomarkers for the diagnosis of pituitary tumors, as well as for predicting or detecting recurrence after surgery. Here we review the biological significance of miRNAs in pituitary tumors and the potential value of circulating miRNAs as biomarkers. ABBREVIATIONS: ACTH, adrenocorticotropic hormone AGO, argonaute AKL, α-Klotho GH, growth hormone HCC, hepatocellular carcinoma HDL, high-density lipoprotein miRNA, microRNA NFA, nonfunctioning adenoma nt, nucleotide pre-miRNA, precursor micro-ribonucleic acid PRL, prolactin

Original Article: http://journals.lww.com/neurosurgery/Fulltext/2014/08000/MicroRNAs_as_Biomarkers_in_Pituitary_Tumors.22.aspx